Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Acquires 548,580 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 548,580 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $7.91 per share, for a total transaction of $4,339,267.80. Following the transaction, the director owned 16,231,717 shares of the company’s stock, valued at approximately $128,392,881.47. This represents a 3.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $8.00 on Friday. The company has a market cap of $197.76 million, a P/E ratio of -2.26 and a beta of 2.38. The stock’s fifty day moving average price is $8.89 and its two-hundred day moving average price is $6.12. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday. Finally, HC Wainwright increased their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter worth about $41,000. Bank of America Corp DE lifted its holdings in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter worth $53,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth about $58,000. Finally, Jane Street Group LLC bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth about $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.